Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER Acorda Therapeutics, 13 Aug 2012 Accessed on 5 Sep 2012 from http://ir.acorda.com/phoenix.zhtml?c=194451&p=irol-newsOtherArticle&ID=1724941&highlight=. CommentRecommendBookmarkWatch